Ortec International Inc.

Development and commercialisation of its proprietary technology, OrCel®.

In 1991, Ortec was founded (U.S.) to commercialise OrCel® with the potential to heal skin wounds resulting from epidermolysis bullosa, burns, venous and diabetic skin ulcers.

Costa Papastephanou, PhD, President & CEO
Mel Silberklang, CSO & Vice President, Research & Development
Alan W. Schoenbart, CFO
Dan Lesnoy, Director of Biomaterials

John R. Leone
Shepard M. Goldberg
Mark Bagnall
Raphael Hofstein
Andreas Vogler

3960 Broadway
New York, NY 10032
USA
Phone: +1-212-740-6999
Fax: +1-212-740-6963

OrCel® has received FDA approval for use in treatment of donor site wounds in burn victims and the approval to market OrCel® to epidermolysis bullosa (EB) patients under a Humanitarian Device Exemption (HDE) application. OrCel® is a bilayered cellular matrix in which normal human allogeneic skin cells are cultured in two separate layers into a type I bovine collagen sponge. Donor dermal fibroblasts are cultured on/ within the porous sponge side; keratinocytes are cultured on the coated, non-porous side of the collagen matrix.

Ortec is currently conducting clinical trials evaluating the safety and efficacy of OrCel® in patients suffering from venous leg ulcers and diabetic foot ulcers.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.